Melior Discovery

About

Melior Discovery is a private biopharmaceutical company located in Exton, Pennsylvania, founded in 2005 by Dr. Andrew Reaume and Dr. Michael Saporito. The company specializes in in vivo pharmacology services, focusing on drug repositioning and the development of new therapeutic candidates. Melior is recognized for its proprietary phenotypic screening platform, *thera*TRACE®, which aids in identifying new therapeutic potentials for drug candidates. The company offers a variety of services, including in vivo pharmacology evaluations across over 80 validated animal models, contract research organization (CRO) services such as pharmacokinetic evaluations and bioanalytical testing, and drug repositioning to discover new indications for existing drugs. Melior Discovery has developed its own pipeline of therapeutic candidates, including MLR-1023, a type 2 diabetes therapeutic that received FDA approval for an Investigational New Drug application in 2009. The company collaborates with major pharmaceutical firms like Pfizer, Merck & Co., Johnson & Johnson, and AstraZeneca, enhancing its capabilities in drug development. In 2024, Melior was named Contract Research Organization of the Year by Life Sciences Review magazine.